SAN MATEO, Calif.–(BUSINESS WIRE)–Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance, plans to announce financial results for the first quarter fiscal year 2024 after market close on Tuesday, February 6, 2024.
Model N will host a webcast at 2:00pm PT (5:00pm ET) on Tuesday, February 6, 2024 to discuss the results.
The news release with the financial results and a link to the webcast will be accessible at the MODN investor relations website (investor.modeln.com). A replay of the webcast will also be available on MODN’s investor relations website.
About Model N
Model N is the leader in revenue optimization and compliance for pharmaceutical, medtech and high-tech innovators. Our intelligent platform powers your digital transformation with integrated technology, data, analytics, and expert services that deliver deep insight and control.
Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology. For more information, visit www.modeln.com.
Contacts
Investor Relations Contact:
Carolyn Bass
Market Street Partners
investorrelations@modeln.com
Public Relations
BLASTmedia
modeln@blastmedia.com
Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…